{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:16:09Z","timestamp":1767903369732,"version":"3.49.0"},"reference-count":10,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.3201\/eid2504.181689","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T13:56:42Z","timestamp":1551362202000},"page":"841-843","source":"Crossref","is-referenced-by-count":24,"title":["Combination of Clindamycin and Azithromycin as Alternative Treatment for <i>Toxoplasma gondii<\/i> Encephalitis"],"prefix":"10.3201","volume":"25","author":[{"given":"Daisuke","family":"Shiojiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ei","family":"Kinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuji","family":"Teruya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2504.181689-201903162233-R1","unstructured":"US Department of Health and Human Serivces. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents [cited 2018 Aug 23]. https:\/\/aidsinfo.nih.gov\/guidelines"},{"key":"key-10.3201\/eid2504.181689-201903162233-R2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/hiv.12402","article-title":"A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?","volume":"18","author":"Hernandez","year":"2017","journal-title":"HIV Med"},{"key":"key-10.3201\/eid2504.181689-201903162233-R3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.diagmicrobio.2014.02.014","article-title":"Comparison of loop-mediated isothermal amplification (LAMP) and nested-PCR assay targeting the RE and B1 gene for detection of Toxoplasma gondii in blood samples of children with leukaemia.","volume":"79","author":"Fallahi","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key-10.3201\/eid2504.181689-201903162233-R4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/clinids\/22.2.268","article-title":"Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.","volume":"22","author":"Katlama","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2504.181689-201903162233-R5","first-page":"1107","article-title":"Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance.","volume":"10","author":"Katlama","year":"1996","journal-title":"AIDS"},{"key":"key-10.3201\/eid2504.181689-201903162233-R6","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1128\/AAC.39.7.1530","article-title":"In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii.","volume":"39","author":"Fichera","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2504.181689-201903162233-R7","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1128\/AAC.42.11.3014","article-title":"Penetration of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphate in patients with AIDS.","volume":"42","author":"Gatti","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2504.181689-201903162233-R8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijid.2004.05.004","article-title":"Cerebral toxoplasmosis treated with clindamycin alone in an HIV-positive patient allergic to sulfonamides.","volume":"9","author":"Yapar","year":"2005","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid2504.181689-201903162233-R9","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1128\/AAC.02009-15","article-title":"Clinically available medicines demonstrating anti-toxoplasma activity.","volume":"59","author":"Neville","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2504.181689-201903162233-R10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/00002030-200103300-00007","article-title":"Dose-escalation, phase I\/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.","volume":"15","author":"Jacobson","year":"2001","journal-title":"AIDS"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/25\/4\/18-1689_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:28:19Z","timestamp":1732987699000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/25\/4\/18-1689_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2504.181689","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}